Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAC-1 and Entrectinib in Metastatic Uveal Melanoma
NCT04589832Phase 2Terminated
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PAC-1 in Uveal melanoma (UM). Started Jan 2021; status: terminated.
02
Drugs
PAC-1
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT04589832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04589832.